AstraZeneca Inks Back-Loaded $1.15B Deal For US Drugmaker
The transaction — one of the biggest in recent memory for an unproven drug pipeline — makes heavy use of the deferred payment structure common in the space. AstraZeneca will pay $560 million in cash up front, and up to $590 million more if Pearl's drugs hit certain development, regulatory and sales milestones.
California-based Pearl focuses...
To view the full article, register now.